Home › Research › Treatments
Efficacy and Safety of Donanemab in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
Hu G, Zhang M.. Current Alzheimer research, 2026-03-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Donanemab is a monoclonal antibody targeting amyloid-β plaques. This study aims to quantify donanemab's consistent cognitive benefits, biomarker efficacy, and safety risks by pooling data from all available RCTs. Materials and methods Systematic searches were conducted in PubMed, the Cochrane Library, Web of Science, and Embase. Phase II/III randomized controlled trials comparing donanemab with placebo in amyloid-positive early Alzheimer's disease were included. After screening 133 records, two trials met the inclusion criteria. Results Donanemab significantly reduced cognitive decline (iADRS +2.93; 95% CI: 1.52- 4.33; P < 0.0001) and functional progression (CDR-SB -0.66; 95% CI: -0.90 to -0.42; P < 0.00001), with amplified benefits in low/medium tau burden patients (iADRS +3.80; 95% CI: 2.10- 5.50). Amyloid clearance was dramatically higher with donanemab (risk ratio (RR) = 234.46; 95% CI: 68.17-806.38; P < 0.00001), with 76.4% achieving amyloid-negative status. There were significantly elevated risks of ARIA-E (RR = 12.90; 95% CI: 8.15-20.43; P < 0.00001), ARIA-H (RR = 2.86; 95% CI: 1.61-5.06; P = 0.0003), and treatment discontinuation (RR = 3.26; 95% CI: 2.38- 4.47; P < 0.00001), whereas all-cause mortality was not significantly different (RR = 1.44; 95% CI: 0.69-3.00). Discussion Donanemab showed statistically significant cognitive benefits, but its clinical meaningfulness warrants careful interpretation. The iADRS improvement of 2.93 points and the CDRSB reduction in all patients of 0.66 points did not approach their minimal clinically important difference (MCID). Conclusion Donanemab provides statistically significant but modest benefits in early AD, particularly in low-tau subgroups. However, the magnitude of cognitive and functional improvement did not approach the threshold for a MCID in the overall population, which requires stringent safety monitoring for ARIA. Clinical implementation should prioritize PET stratification and APOEguided surveillance.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hu, G., & Zhang, M. (2026). Efficacy and Safety of Donanemab in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. Current Alzheimer research. https://doi.org/10.2174/0115672050425914260119063736
Vancouver
Hu G, Zhang M. Efficacy and Safety of Donanemab in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. Current Alzheimer research. 2026. doi:10.2174/0115672050425914260119063736. PMID: 41879436.
BibTeX
@article{hu2026-41879436,
author = {Hu, G. and Zhang, M.},
title = {{Efficacy and Safety of Donanemab in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis}},
journal = {Current Alzheimer research},
year = {2026},
doi = {10.2174/0115672050425914260119063736},
pmid = {41879436},
url = {https://doi.org/10.2174/0115672050425914260119063736}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Donanemab significantly reduced cognitive decline (iADRS +2.93; 95% CI: 1.52- 4.33; P < 0.0001) and functional progression (CDR-SB -0.66; 95% CI: -0.90 to -0.42; P < 0.00001), with amplified benefits in low/medium tau burden patients (iADRS +3.80; 95% CI: 2.10- 5.50).
- There were significantly elevated risks of ARIA-E (RR = 12.90; 95% CI: 8.15-20.43; P < 0.00001), ARIA-H (RR = 2.86; 95% CI: 1.61-5.06; P = 0.0003), and treatment discontinuation (RR = 3.26; 95% CI: 2.38- 4.47; P < 0.00001), whereas all-cause mortality was not significantly different (RR = 1.44; 95% CI: 0.69-3.00).
- Discussion Donanemab showed statistically significant cognitive benefits, but its clinical meaningfulness warrants careful interpretation.
- Conclusion Donanemab provides statistically significant but modest benefits in early AD, particularly in low-tau subgroups.
- However, the magnitude of cognitive and functional improvement did not approach the threshold for a MCID in the overall population, which requires stringent safety monitoring for ARIA.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect size76.4%; RR = 12.90; RR = 2.86
- Evidence strengthHigh
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 32 of the 58 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current Alzheimer research) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41879436) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 32 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 58 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “donanemab”
6 studies in the library carry the topic tag “donanemab”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 6 tagged studies.